News Releases

WESTLAKE VILLAGE, Calif. , Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co.

WESTLAKE VILLAGE, Calif. , Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The Company initiated its second lung cancer trial,

WESTLAKE VILLAGE, Calif. , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming

– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer – – Trial represents second indication in the clinic for Olvi-Vec via systemic

WESTLAKE VILLAGE, Calif. , Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place

WESTLAKE VILLAGE, Calif. , Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in

WESTLAKE VILLAGE, Calif. , Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates.   “The past quarter has continued to be

WESTLAKE VILLAGE, Calif. , July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in

WESTLAKE VILLAGE, Calif. , May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation ( Genelux ) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000

WESTLAKE VILLAGE, Calif. , May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation ( Genelux ) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants.